How many insider trades does FilingIQ track for VXRT?

FilingIQ tracks 262 Form 4 insider transactions for VXRT (Vaxart, Inc.), covering filings from Feb 15, 2018 onwards. 5 of those are dated within the last 90 days.

Are VXRT insiders net buyers or net sellers?

Across the full Form 4 history for VXRT, 47 transactions (18%) were open-market purchases and 63 (24%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VXRT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is VXRT in?

Vaxart, Inc. (VXRT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $368.37M.

VXRT insider trading

NasdaqGS Healthcare

Vaxart, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

262

Last 90 days

Buys / sells

18% / 24%

Market cap

$368.37M

About Vaxart, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Company website: ateapharma.com

VXRT insider activity at a glance

FilingIQ tracks 262 insider transactions for VXRT in filings since Feb 15, 2018. The most recent transaction is dated Jul 16, 2026.

Across the full history, 47 open-market purchases and 63 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VXRT insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VXRT trades on FilingIQ Raw filings on SEC EDGAR

Latest VXRT Form 4 filings

Grasman Jeroen Nicolaas Chief Financial Officer

F May 21, 2026

BREITMEYER JAMES B

A May 1, 2026

Tucker Sean SVP, Chief Scientific Officer

F Mar 31, 2026

Cummings James F. Chief Medical Officer

F Mar 31, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for VXRT?: FilingIQ tracks 262 Form 4 insider transactions for VXRT (Vaxart, Inc.), covering filings from Feb 15, 2018 onwards. 5 of those are dated within the last 90 days.
Are VXRT insiders net buyers or net sellers?: Across the full Form 4 history for VXRT, 47 transactions (18%) were open-market purchases and 63 (24%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VXRT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is VXRT in?: Vaxart, Inc. (VXRT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $368.37M.

Methodology & sources

Every VXRT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.